Moderna Soars over 5% on Positive Cancer Therapy Results and Analyst Upgrade

TigerJan 22, 2026 9:52 AM

View all comments（0）



Moderna saw its stock price soar 5.12% in pre-market trading, continuing its strong momentum from the previous session. The surge is driven by positive clinical trial results for Moderna's experimental skin cancer vaccine developed in collaboration with Merck & Co. The Phase 2b study showed that adding Moderna's intismeran autogene to KEYTRUDA significantly reduced the risk of recurrence or death in melanoma patients, with sustained benefits over five years.

Additionally, Bernstein raised Moderna's target price to $35 from $25, reflecting increased confidence in the company's growth trajectory. These developments have fueled investor optimism, leading to the stock's pre-market rally.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Qualcomm Stock Forecast: Can QCOM Hit $200 After Amazon AI Chip Partnership?

TradingKey - Qualcomm (QCOM) is accelerating its entry into the AI data center market, and its latest partnership with Amazon (AMZN) could mark a significant step in this strategic transformation.

Copper Price Forecast: US Refined Copper Tariffs May Be Delayed, Copper Prices Plunge After Record High, Can They Still Rise?

TradingKey - On September 9, copper prices hit an all-time high of $14,854, but subsequent changes in U.S. refined copper tariff policy triggered a sharp drop on Thursday, with prices plunging 4.48% on the day to close at $14,169.

Tesla Stock Price Forecast: Morgan Stanley Sees Semi Truck Generating $17 Billion in Software Revenue, Can the Stock Continue Its Recovery?

On September 11, Tesla (TSLA) officially unveiled the European-spec version of the Semi and confirmed that customer deliveries will begin in 2027. Tesla is expected to showcase the physical vehicle and release further market rollout details at the IAA Transportation commercial vehicle show in Hanover (September 15–20). Meanwhile, Morgan Stanley noted in its latest research report that Tesla is becoming a "credible emerging competitor" in the autonomous trucking sector, significantly raising its bull-case valuation for the company's autonomous truck business.

Anthropic Targets $2 Trillion Valuation as 2026 US IPO Proceeds Hit Record, Yet New Stocks Lag Market

TradingKey - US IPO proceeds in 2026 have reached a record high, but post-IPO stock performance has not strengthened in tandem. As companies like Oura and Anthropic move forward with their listings, September and October will further test investor appetite for high-valuation new stocks.

Qualcomm Stock Holds Rising Trendline as Amazon AI Deal Puts $182.70 Breakout in Focus

TradingKey - Qualcomm stock forecast, QCOM technical analysis, Qualcomm Amazon AI deal, Dragonfly data center, Qualcomm automotive growth

Featured Tools